Finally, the phase II clinical trial ILUSTRO (NCT03505320) is evaluating the novel antibody Zolbetuximab in different combinations: Zolbetuximab monotherapy or associated with immunotherapy and/or standard chemotherapy in gastric cancer patients (including HER2-positive disease) after at least two previous treatment lines. Here, ERBB2 is linked to gastric cancer.